## <u>Drug Injury Watch: Cardiovascular Safety Issues For Onglyza</u> <u>And Kombiglyze Will Be Discussed At April 2015 FDA Advisory</u> Committee Meeting

## These Two New AstraZeneca Diabetes Medications With Saxagliptin Are Part Of The Incretin Mimetic Class Of Drugs

(Posted by Tom Lamb at www.DruglnjuryWatch.com on March 9, 2013)

**SUMMARY**: To start, for some background, one might want to read this article, <u>"Possible Link</u> Between Heart Failure And Onglyza Diabetes Type 2 Drug Is Being Investigated By FDA, As <u>Announced In February 2014"</u>, which we posted about a year ago.

At an April 14, 2015 meeting of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee, results of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial for for AstraZeneca's relatively new diabetes drugs Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin HCI extended-release) will be discussed.

Besides saxagliptin (Onglyza, Kombiglyze XR), other diabetes drugs in the incretin mimetic class besides include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto).

We will watch for further developments surrounding the safety profile of Onglyza and Kombiglyze XR as well as these other incretin mimetic diabetes drugs.

[Read this article in full at original source]

## Earlier articles by attorney Tom Lamb on the Side Effects Blog:

- <u>First 2015 Update On Fosamax Femur Fracture Litigation: Not Much New Information To</u>
   Report Out
- A New Case Of Progressive Multifocal Leukoencephalopathy (PML) In A Patient Using Gilenya Is Reported By Novartis In Canada
- Various Drug Safety Issues Continue To Be Associated With Novartis Multiple Sclerosis
   (MS) Medication Gilenya

- Zofran Associated With Birth Defects When Used During Pregnancy As An "Off-Label"
   Morning Sickness Treatment
- Viagra / Cialis / Levitra: Prostate Cancer Recurrence When Used After Radical
   Prostatectomy Surgery

Attorney Tom Lamb represents people in personal injury and wrongful death cases involving unsafe prescription drugs or medication errors. The above article was posted originally on his blog, **Drug Injury Watch** – with live links and readers' Comments.

<a href="http://www.DrugInjuryWatch.com">http://www.DrugInjuryWatch.com</a>